Center for Pediatric Oncology and Hematology

Center for Pediatric Oncology and Hematology

Pauline Allen Gill Center for Cancer and Blood Disorders

95+ clinical trials, 900+ annual patients, 1 amazing team

As the largest cancer and blood disease program in North Texas, and one of the largest in the U.S., Children’s Health℠ provides care for more than 350 children with newly-diagnosed cancer and more than 600 children with newly-diagnosed blood disease each year.

Children’s Health is the only pediatric cancer program affiliated with the UT Southwestern Harold C. Simmons Comprehensive Cancer Center. As the only National Cancer Institute-designated comprehensive cancer center in North Texas, we are always pushing to discover new treatments. We offer patients the ability to participate in the broadest possible range of clinical trials, giving access to potential therapies not available at other facilities.

Dallas

214-456-2382

Plano

469-303-4400

Referrals

214-456-2978

Stay Connected

Refer a Patient with Pediatric Oncology and Hematology (CCBD)

Accepted Insurance Plans

Highlights

Heart doctors at Children's Health analyze a patient's imaging results

FUVID Study: Functional Characterization of Children with Chronis Venous Thromboembolic Disease

A multi-center, prospective study evaluating exercise intolerance and dyspnea on exertion in patients following first-episode pulmonary embolism with or without deep venous thrombosis.

Learn more about the clinical trial.

 

Our Programs

Clinical Trials & Research

Our nationally-recognized team is committed to eradicating childhood cancer and blood disease through research & innovation. Children’s Health's partnership with UT Southwestern enables patients to access some of the latest treatments and clinical trials available. Learn more about our leading experts and cutting-edge research programs.

Check out some of our recent clinical trials:

UCART19 in Pediatric Patients with Relapsed/Refractory B Acute Lymphoblastic Leukemia

This study aims to evaluate the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL). 

 

Conferences and Events

Many of our conferences and events offer continuing education credits.

Check out some of our upcoming events:

Meet the Care Team